Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance-Reference-Cited by-同舟云学术

Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

Published:2013-12-10 Issue:5 Volume:20 Page:1204-1211
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Chen Zhao,Akbay Esra,Mikse Oliver,Tupper Tanya,Cheng Katherine,Wang Yuchuan,Tan Xiaohong,Altabef Abigail,Woo Sue-Ann,Chen Liang,Reibel Jacob B.,Janne Pasi A.,Sharpless Norman E.,Engelman Jeffrey A.,Shapiro Geoffrey I.,Kung Andrew L.,Wong Kwok-Kin

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer—A Validation Study;International Journal of Molecular Sciences;2024-03-23

2. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions;Expert Opinion on Investigational Drugs;2024-02-23

3. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation;Journal of Experimental Medicine;2024-01-29

4. A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance;Acta Pharmaceutica Sinica B;2024-01

5. miRNA-Seq Tissue Diagnostic Signature: A Novel Model for NSCLC Subtyping;International Journal of Molecular Sciences;2023-08-28